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Abstract 
Background: Patients with common variable immunodeficiency (CVID) suffer frequent 
respiratory tract infections despite immunoglobulin replacement, and are prescribed 
significant quantities of antibiotics. The clinical and microbiological nature of these 
exacerbations, the symptomatic triggers to take antibiotics and the response to treatment have 
not been previously investigated. 
 
Objective: To describe the nature, frequency, treatment and clinical course of respiratory tract 
exacerbations in patients with CVID, and to describe pathogens isolated during respiratory 
tract exacerbations. 
 
Methods: We performed a prospective diary card exercise in 69 CVID patients recruited from 
a primary immunodeficiency clinic in the UK, generating 6210 days of symptom data. We 
collected microbiology (sputum microscopy and culture, atypical bacterial PCR, 
mycobacterial culture) and virology (nasopharyngeal swab multiplex PCR) samples from 
symptomatic CVID patients. 
 
Results: There were 170 symptomatic exacerbations, and 76 exacerbations treated by 
antibiotics. The strongest symptomatic predictors for commencing antibiotics were cough, 
shortness of breath and purulent sputum. There was a median delay of 5 days from the onset 
of symptoms to commencing antibiotics. Episodes characterised by purulent sputum 
responded more quickly to antibiotics while sore throat and upper respiratory tract symptoms 
responded less quickly. A pathogenic virus was isolated in 56% of respiratory exacerbations 
and a potentially pathogenic bacteria in 33%. 
 
Conclusions: Patients with CVID delay and avoid treatment of symptomatic respiratory 
exacerbations which could result in structural lung damage. However, viruses are commonly 
represented and illnesses dominated by upper respiratory tract symptoms respond poorly to 
antibiotics, suggesting that antibiotic usage could be better targeted. 
 
Abstract word count: 248 
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Take home message for social media:  CVID patients delay antibiotics for respiratory tract 
infections. Many Infections are associated with viruses. 
 
Highlights box:  
What is already known about this topic?  Even with immunoglobulin replacement 
respiratory tract infections remain the commonest clinical feature in CVID and impair quality 
of life.  Encapsulated bacteria are thought to be the most common pathogens.  
 
What does this article add to our knowledge? This is the first detailed description of 
respiratory exacerbations in CVID, capturing 6210 days of data. Viruses are commonly 
represented. There is a delay in commencing antibiotic therapy and the response to antibiotic 
therapy depends on the symptomatic presentation. 
 
How does this study impact current management guidelines?  Since viral infections are 
common in CVID, antibiotic therapy should be considered with caution.  However, self-
administered antibiotic therapy should be started more promptly with symptoms of cough and 
purulent sputum. 
 
Keywords: Respiratory tract exacerbations; common variable immunodeficiency; antibiotics; 
viral infection 
 
Abbreviations 
COPD - Chronic obstructive pulmonary disease  
CT - X-ray computed tomography 
CVID  - Common Variable Immunodeficiency 
HR - Hazard ratio  
IQR - Interquartile range 
IR - Odds ratio 
OAT - Oral antibiotic therapy 
PCR - polymerase chain reaction 
SD - Standard deviation 
SGRQ - St George’s Respiratory Questionnaire 
TE - Treated exacerbation 
TSE  - Treated symptomatic exacerbation 
USE - Untreated symptomatic exacerbation 
 
More detailed methodology and accompanying figures are provided in an online 
supplement. 
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Introduction 
Common Variable Immunodeficiency (CVID) is a heterogeneous primary immunodeficiency, 
in which patients fail to produce adequate levels of immunoglobulins.  With a prevalence 
between 1 in 10,000 and 1 in 50,000, it is the most common symptomatic primary 
immunodeficiency.1-4 
 
Despite adequate immunoglobulin replacement, recurrent respiratory tract infections are the 
commonest clinical feature in CVID2,5, and can result in progressive bronchiectasis.6-9  
Respiratory tract infections were thought to be caused largely by encapsulated bacteria.6,10  
However, recent evidence has accumulated for a significant burden of viral infection.11,12 
 
Despite the high incidence of respiratory tract infections and their negative influence on 
quality of life in primary antibody deficiency syndromes13, the nature of symptoms during 
these episodes remain unknown.  Patients are often prescribed antibiotics to mitigate 
respiratory tract infections, both as ‘rescue’ courses to promptly self-administer for acute 
events and as prophylaxis to reduce infection frequency.  However, the symptomatic triggers 
for taking breakthrough antibiotics and the clinical response to these treatments are not 
known.   
 
In this prospective study, we sought to answer these questions by systematically recording 
daily symptoms and treatment in a cohort of CVID patients over a winter period.  In a parallel 
analysis, we also explored bacterial and viral pathogens encountered during acute respiratory 
symptoms in CVID patients. 
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Methods 
Participants 
Patients were recruited from the joint Immunology-Respiratory service at the Royal Free 
Hospital, London, UK.  Patients had a diagnosis of CVID made by a clinical immunologist 
following the Pan-American Group for Immunodeficiency and the European Society for 
Immunodeficiencies definitions.14  All were receiving immunoglobulin replacement and under 
regular (at least 6-monthly) clinical review.  The only exclusion criterion was inability to 
provide informed consent.  All participants provided written, informed consent (REC 
04/Q0501/119). 
 
Study design  
For this observational, prospective cohort study, patients completed daily checkbox symptom 
diaries for 90 days between December 2014 and February 2015, covering the UK winter 
season.  Participants were asked to report new or increased respiratory symptoms from a 
predefined list (Table 1).  Chronic or stable symptoms were not to be reported.  Definitions of 
symptoms and instructions for diary completion were clearly explained; further details are 
provided in the online supplement.  We have previously used such methodology in other 
chronic respiratory diseases.15 Participating patients were also asked to complete the St 
George’s Respiratory Questionnaire (SGRQ), a validated measure of respiratory health-status 
scored between 0 (best) and 100 (worst) quality of life.16  
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Simultaneously, but independently from the described study, we conducted a cross-sectional 
study in which patients experiencing acute respiratory symptoms provided samples 
(nasopharyngeal swabs and spontaneously expectorated sputum) for bacterial and viral 
testing.  Sputum was considered purulent when more than 10 granulocytes per high power 
field were found.  Samples were either collected by clinic staff or, after careful instruction on 
sampling, submitted directly from patients by mail. 
 
Figure 1 summarises the two investigations undertaken on the cohorts. 
 
Definition of exacerbations and variables 
Pre-analysis, we grouped clinically related symptoms as indicated in Table 1.  For calculation 
of total symptom count, each symptom was counted individually for each patient and each 
day.  Cumulative total symptom count is the sum over all days of an exacerbation period. 
 
We utilised two definitions of exacerbation, based either on symptoms or healthcare 
utilisation.  Similar methodology has been reported and validated in COPD17.  For the first 
definition, we identified a symptomatic exacerbation as an event of two or more new 
symptoms lasting for two or more consecutive days as recorded by the patient on their diary, 
whether or not they received additional treatment.  The start of a symptomatic exacerbation 
episode was the first day of two or more new symptoms lasting for two or more consecutive 
days.  The end of the episode was the last consecutive day with two or more symptoms 
(allowing symptoms to change over time).  If oral antibiotic therapy (OAT) was used during a 
symptomatic exacerbation episode, this was termed a treated symptomatic exacerbation 
(TSE).  If not, it was an untreated symptomatic exacerbation (USE).  
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We defined a healthcare utilisation exacerbation as use of OAT for worsening respiratory 
symptoms.  We call this a treated exacerbation (TE) event, and if it coincided with diary-
defined symptoms it would be a TSE.  The episode was considered to last from the first day 
on which a symptom occurred until recovery, defined as the last day of any symptom which 
was present when OAT was started.  Additional details regarding exacerbation and variable 
definitions are provided in Supplementary Methods. 
 
Data handling and statistical analysis  
Statistical analysis was performed using Stata v14.0 (StataCorp LP, College Station, TX, 
USA).  Continuous variables are presented as median and 1st and 3rd quartiles or by mean and 
standard deviation (SD) as appropriate.  For categorical and binary variables we present 
frequencies. 
 
Missing data were not imputed.  Results were considered statistically significant at p value 
<0.05.  Data were analysed with logistic regression for trigger symptom analysis, Cox 
regression for antibiotic response analysis, Pearson correlation, Wilcoxon rank-sum test and t 
tests as indicated.  Further details are provided in Supplementary Methods.  
 
Analysis of microbial samples 
A multiplex real-time PCR (RT-PCR) for Adenovirus, Coronavirus (HKU, NL63, OC43 & 
229E), Enterovirus, Human metapneumovirus, Influenza virus (A&B), Parainfluenza virus 
(1,2,3 & 4), Parechovirus, Respiratory syncytial virus, and Rhinovirus was performed in the 
National Health Service Virology laboratories at the Royal Free Hospital.  
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Sputum samples were examined by microscopy and culture for bacteria and mycobacteria 
plus in-house multiplex RT-PCR for Chlamydia pneumoniae, Legionella pneumophila and 
Mycoplasma pneumoniae.  Further details are provided in Supplementary Methods. 
 
We included multiple samples from a single patient if separated by at least two weeks and the 
patient was asymptomatic between episodes.  Airway colonisation by pathogenic bacteria was 
diagnosed when the same organism had been isolated more than twice within the two years 
before our study. 
 
 
Results 
Study population 
134 CVID patients were given a diary.  69 (51%) patients returned a diary after completion of 
the study period, providing 6210 days of data (Figure 1). Demographic and clinical 
characteristics of included patients are presented in Table 2.  Patients who completed a diary 
are older (median (IQR) 59.36 (46.74–68.22) vs 45.02 (36.33–53.79) years; p<0.001) and  
have a higher bronchiectasis severity index (median (IQR) 3.5 (2–6) vs 2 (1-4); p=0.01) than 
those who did not.  
 
Patients with CVID suffer frequent respiratory exacerbations and often use antibiotics 
During the study period, there were 170 symptomatic exacerbation events (mean 0.82 per 
patient month).  75 (mean 0.36 per patient month) of these events were treated by OAT whilst 
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95 (mean 0.46 per patient month) were not.  Nine patients had no symptomatic exacerbations 
during the period.  Published literature suggests that 106 courses of antibiotics were 
prescribed per 1,000 men and 155 per 1,000 women for respiratory tract infections by general 
practitioners in the UK in 2014.18  This corresponds to 2.3 courses of antibiotics in total (0.01 
per patient month) prescribed to a group similar to our cohort in the general population during 
three months.  
Treated symptomatic exacerbation (TSE) episodes were more severe than untreated (USE) in 
terms of cumulative total symptom count (median (IQR) 40 (24-82) vs 12 (6-30) symptoms; 
p<0.001) and episode duration (median duration 10 v 4 days; HR 0.54; p<0.001).   
 
76 treated exacerbations (TE) were covered within our study period.  One TE did not meet the 
criteria of TSE.  The median (IQR) duration of TE episodes was 14 (9-19) days; median 
(IQR) time from the start of symptoms until OAT was 5 (2-7) days; and median (IQR) time 
until recovery was 6.5 (5-14) days.  Median (IQR) duration of therapy was 14 (7-14) days.  A 
detailed description of symptom prevalence is provided in Figure 2.  As treatment, patients 
used Co-amoxiclav for 23 (30%) exacerbations, Amoxicillin for 20 (26%), Doxycycline for 
12 (16%), Ciprofloxacin for 10 (13%), Clarithromycin for 7 (9%), and Azithromycin, 
Erythromycin, Flucloxacillin, and Levofloxacin each for one (1%) exacerbation.   
 
Cough, shortness of breath and purulent sputum are the strongest triggers for patients 
to initiate antibiotic therapy 
We compared 76 days on which OAT was started with 5370 days without OAT.  764 days 
comprising the remainder of the antibiotic courses were ignored.  In univariate analysis, all 
symptoms were positively and significantly associated with start of OAT.  Cough (odds ratio 
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(OR) 48.70; 95%-CI 24.02–111.47), purulent sputum (OR 25.26; 95%-CI 15.25–42.49), 
increased sputum volume (OR 23.85; 95%-CI 13.85-42.70), and shortness of breath (OR 
17.27; 95%-CI 10.54–28.22) showed the highest ORs (Figure 3A).  In multivariate analysis, 
only cough (OR 13.00; 95%-CI 5.93-28.47), purulent sputum (OR 6.30; 95%-CI 1.19–33.40), 
and shortness of breath (OR 2.41; 95%-CI 1.31–4.46) remain significant when adjusted for 
other symptoms (Figure 3A).   
In univariate analysis, time since start of symptoms was not positively associated with start of 
OAT, and instead patients started OAT at a fairly constant rate over the first 12 days of 
symptoms (Figure 3B).  There was, however, a significant positive association between total 
symptom count and start of OAT (OR 2.19; 95%-CI 1.96–2.43), suggesting an approximate 
doubling of the odds to start OAT for each additional symptom.  The mean (SD) number of 
symptoms on days on which OAT was started was 4.97 (1.94) versus 0.86 (1.55) symptoms on 
days when antibiotics were not taken (p<0.001).   
 
Exacerbations characterised by purulent sputum respond rapidly to antibiotics, while 
those characterised by upper respiratory tract symptoms and sore throat respond more 
slowly 
Median (IQR) time until recovery after start of OAT in all treated exacerbations was 6.5 (5-
14) days (Figure 4A).  In 56% of treated exacerbations time until recovery was ≤7 days; in 
81% it was ≤14 days. 
In univariate analysis, time until recovery was longer in the presence of upper respiratory tract 
symptoms (median 8 vs 5 days; hazard ratio (HR) 0.50; p=0.03; Figure 4B), sore throat (12 vs 
6 days; HR 0.54; p=0.007; Figure 4C) or white sputum (12 vs 6 days; HR 0.63 p=0.03) on the 
day before commencing OAT.  However, time until recovery was shorter in exacerbations in 
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which purulent sputum was present (6 vs 13 days; HR 1.98; p=0.02; Figure 4D).  In 
multivariate analysis, upper respiratory tract symptoms, sore throat and purulent sputum were 
significant independent predictors for response to OAT (Figure 4E). 
There was no statistically significant correlation between time until starting OAT and time 
until recovery nor between total symptom count on the day before OAT was started and 
subsequent time until recovery.  However, a longer time until starting OAT was associated 
with a longer  episode duration (HR 0.92; p<0.001). 
 
Patients taking prophylactic antibiotics have more untreated exacerbations and wait 
longer from the onset of symptoms to initiate breakthrough antibiotics, while patients 
with bronchiectasis have more treated exacerbations. 
 
We proceeded to investigate whether the frequency and nature of exacerbations were affected 
by antibiotic prophylaxis or by the presence of bronchiectasis. The number of symptomatic 
exacerbations (total, treated and untreated) were analysed with two (prophylactic antibiotics) 
by two (bronchiectasis) ANOVAs.   
There were more symptomatic exacerbation events in patients on prophylactic antibiotics than 
in patients not on prophylaxis (mean (SD) 2.87 (2.21) vs 1.71 (1.33), p=0.03).  This difference 
was explained by more untreated symptomatic exacerbations in patients on prophylactic 
antibiotics (mean (SD) 1.78 (2.14) vs 0.63 (0.88), p=0.03).  In contrast, patients with 
bronchiectasis experienced similar overall numbers of exacerbations and untreated 
exacerbations versus those without bronchiectasis, but more treated symptomatic 
exacerbations (mean (SD) 1.27 (1.15) vs 0.81 (1.08), p=0.04). Interaction effects were non-
significant in all three analyses, suggesting that the effect of prophylaxis did not differ 
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between patients with or without bronchiectasis, and that the increased frequency of treated 
exacerbations in bronchiectatic patients persisted regardless of prophylaxis. 
Regarding the impact of antibiotic prophylaxis on exacerbation severity, there was no 
significant difference in episode duration or cumulative total symptom count during 
symptomatic exacerbations between patients on or off prophylactic antibiotics.  Patients 
taking prophylactic antibiotics waited longer before starting oral antibiotic treatment for 
breakthrough infections (median 6 vs 3 days; HR 0.55; p=0.03).  However, time until 
recovery after commencing OAT was not significantly different between patients on or off 
prophylactic antibiotics. 
There were no significant differences between patients with or without bronchiectasis in 
exacerbation severity, time until OAT, and time until recovery. 
Prospective symptoms correlate modestly with cross-sectional analysis of quality of life  
There was moderate correlation between the SGRQ Total Score and the number of days on 
which new cough (r=0.29, p=0.02), sore throat (r=0.29, p=0.02), shortness of breath (r=0.38, 
p=0.002) and wheeze (r=0.32, p=0.01) were present.  The cumulative total symptom count or 
cumulative number of days of symptomatic exacerbation episodes over the study period also 
correlated with SGRQ Symptom Score (r=0.36, p=0.004) and SGRQ Total Score (r=0.28, 
p=0.03).   
 
Respiratory exacerbations in CVID demonstrate a high frequency of viral and bacterial 
pathogens  
54 naso-pharyngeal swabs were obtained from 41 patients with acute respiratory symptoms.  
Viruses were detected in 30 (56%) exacerbations (Figure 5).  Rhinovirus was the most 
common virus detected (in 18 (33%) exacerbations), including two (4%) co-infections with 
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Respiratory Syncytial Virus, two (4%) co-infections with Adenovirus and one (2%) co-
infection with Human Metapneumovirus. 
 
43 spontaneously expectorated sputum samples were obtained from 34 patients with acute 
respiratory symptoms.  Pathogenic bacteria were isolated in 14 (33%) exacerbations (Figure 
5).  The most common bacteria were Haemophilus influenzae in 8 (19%), Streptococcus 
pneumoniae in two (5%), and Pseudomonas aeruginosa in two (5%) exacerbations.  Two 
patients accounting for four exacerbations were colonised with Haemophilus influenzae as 
defined above.  All samples were negative for mycobacterial culture and PCR for atypical 
pneumonia organisms.   
 
There was bacterial and viral co-infection in 25% of exacerbations; in 27.5% no pathogen was 
found.  Microscopic evidence of purulence as measured by more than 10 granulocytes per 
high power field were found on microscopy in 41% of exacerbations positive for a pathogenic 
virus (whether or not patients produced sputum), in 69% of exacerbations positive for a 
pathogenic virus where contemporaneous sputum was collected and in 64% of exacerbations 
positive for pathogenic bacteria. 
 
 
Discussion 
This is the first prospective cohort study describing symptoms and treatment of respiratory 
tract infection in CVID.  We discovered a clinically important delay in commencing antibiotic 
therapy and that many symptoms are untreated, especially in patients taking prophylactic 
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antibiotics.  Episodes characterised by purulent sputum respond more quickly to antibiotics 
while sore throat and upper respiratory tract symptoms respond less quickly: perhaps 
correspondingly, in many respiratory exacerbations we detected a pathogenic virus.  
 
CVID patients are frequently prescribed antibiotics and educated to promptly take them if 
they suffer ‘break-through’ infections.  However, their actual behaviours in relation to this 
therapy have not previously been documented.  Here, across 6,210 days of data, we 
discovered that individual 'warning' symptoms (cough, shortness of breath, and purulent 
sputum) are the most important triggers for patients to start OAT.  Time since start of 
symptoms is a less important trigger, and the proportion of patients starting therapy each day 
is fairly constant across the first 12 days of symptoms.  Consequently, and despite the fact that 
all patients should have antibiotics available for immediate usage, there is a median delay of 
five days in starting OAT.   We are investigating whether delays to commencing treatment are 
explained more by patient choice or by access to healthcare. 
 
A longer time to commencing therapy did not adversely impact subsequent response to 
antibiotics (measured by time until recovery), but inevitably increases the total length of an 
infectious episode.  Since infections in CVID can lead to structural lung damage2,13, this delay 
may be clinically significant.  Similarly, many exacerbations (95 across the study period) were 
untreated and may not have been reported without prospective data collection.  Indeed, it is 
well documented that untreated symptomatic exacerbations often go unreported in COPD19, 
with up to three times more exacerbations collected by symptom diaries than by interview; 
COPD patients also treat only half of all exacerbations recorded in diaries.20   
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Response to OAT, judged by time until recovery, did not correlate with delay to commencing 
therapy or total symptom count, but depended on individual symptoms.  There was a slower 
response in patients with upper respiratory tract symptoms and sore throat, which we 
hypothesise may be explained by a purely viral aetiology for some of these episodes.  
Conversely, exacerbations with purulent sputum resolved more quickly on antibiotics, perhaps 
indicating a dominant bacterial component.  
 
The number of untreated symptomatic exacerbations, and delay to commencing OAT, were 
higher in patients on prophylactic antibiotics.  This could imply a reluctance to start OAT in 
this group due to over-reliance on prophylaxis or as an increased tolerance of symptoms 
(generally prophylaxis is only instituted in patients with a high background incidence of 
exacerbations). We found no difference in severity or duration of individual symptomatic 
exacerbations with or without prophylaxis:  this could indicate effectiveness of prophylaxis, 
but conversely there is no evidence that prophylaxis attenuates the severity of breakthrough 
exacerbations.  
 
There was a modest correlation between some acute symptoms reported in diaries and the 
SGRQ, which measures the impact of symptoms on health-related quality of life.16  
Cumulative total symptom count and cumulative number of days of symptomatic 
exacerbation over the study period also correlated with SGRQ scores, confirming that 
symptomatic exacerbations have a significant impact on patients.  However, our study design 
only included new or worsening symptoms rather than chronic symptoms, which presumably 
explains only moderate correlation between diary-derived parameters and SGRQ scores.  
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In our analysis of pathogens isolated during symptomatic exacerbations, we detected a virus 
in 56% of patients’ samples.  This is similar to other reports: for example, Kainulainen et al 
reported positive viral PCR in 54% of 65 exacerbations within 12 patients11. Bacterial 
pathogens, most commonly encapsulated organisms, were found in 33% of symptomatic 
exacerbations. 
 
Interestingly, in exacerbations positive for a pathogenic virus but where the patient also 
expectorated sputum, there was evidence of purulence as measured by high microscopic 
granulocyte count in 69% of samples. Although this may be partly explained by underlying 
bronchiectasis in some patients, we frequently observed co-infection with bacteria.  While this 
may represent simply colonising bacteria in the presence of an acute viral exacerbation, there 
is evidence from COPD that rhinovirus infections adversely affect microbiome and the 
prevalence of pathogenic bacteria21,22.  Our earlier results suggest that new or worsening 
purulent sputum predicts rapid response to antibiotic therapy, regardless of the organism 
isolated.  Further research is required to investigate how the pathogens identified here 
influence the balance of other organisms in the respiratory tract and thereby the response to 
antibiotic therapy.  However, our current recommendation would be to promptly treat 
exacerbations characterised by purulent sputum irrespective of virology results, not least 
because neutrophil elastase is significantly implicated in bronchiectasis pathogenesis.22 
 
Our study has some limitations.  It was performed at a single tertiary care centre during the 
winter, when respiratory tract infections are more frequent24,25.  The true incidence of 
symptomatic exacerbations and antibiotic use throughout the year thus cannot not be 
extrapolated.  We cannot exclude that factors particular to our geographic location and 
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particular to the brief study period have influenced our results. 
Due to its design, this study lacks a healthy control group.  We therefore cannot discuss 
differences in quality or quantity of exacerbations between CVID and non-
immunocompromised patients, but available data from other sources18 suggest that the usage 
of antibiotics in our cohort is many times higher than in the general population. 
We only have data from patients who agreed to complete a diary (69 patients) and not the 
entire CVID cohort (134 patients).  This may result in a selection bias, especially since these 
patients are older and have more clinically severe bronchiectasis.  Although our symptomatic 
exacerbations did not differ in number nor severity in patients with or without bronchiectasis, 
generalizability to other CVID patients is limited, as the prevalence of bronchiectasis varies 
throughout centers2.  
The symptomatic definition of a respiratory exacerbation in CVID is not standardised and we 
therefore operated with a simplified definition, which has been validated in COPD17. 
Although patients were carefully instructed to record only new or worse symptoms, we cannot 
exclude the possibility that some reported chronic morbidity.  We note that the mean number 
of ‘new’ symptoms even on days without antibiotic therapy was 0.86; however, this includes 
the period before and after antibiotic therapy in exacerbations, and may also reflect a 
genuinely high frequency of acute symptoms. 
As many patients reside a significant distance from the hospital, we were unable to perform 
microbiology and virology tests on diary-defined exacerbations and thus performed two 
parallel studies (Figure 1).    
 
In summary, we have demonstrated that respiratory exacerbations are extremely common in 
CVID, but that patients delay starting antibiotics and ignore symptoms.  Although viruses 
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were identified commonly, patients should nevertheless be educated to take antibiotics 
promptly if they develop purulent sputum.  
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Tables 
Table 1: List of symptoms collected in diaries and variables used for analysis. 
Variable Values Analysis Group  
(all dichotomous) 
Blocked nose Present, not present Upper respiratory tract symptoms 
Nasal discharge Present, not present 
Sinus Pain Present, not present 
Sore Throat Present, not present Sore Throat 
Cough Present, not present Cough 
Shortness of breath Present,  not present Shortness of breath 
Wheeze Present, not present Wheeze 
Sputum colour White, 
yellow, green,  
not present 
White Sputum 
Purulent Sputum 
Sputum volume Equivalent to tea spoon, egg cup, cup, 
not present 
Increased sputum volume 
 
'Upper respiratory tract symptoms' is generated by combination (inclusive disjunction) of 'blocked nose', 'nasal discharge', 
and 'sinus pain'.  Sputum colour with four possible values was separated into two binary variables.  Sputum volume with four 
possible values was reduced to a binary variable. 
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Table 2: Patient characteristics at study enrolment 
 69 patients who completed 
symptom diaries 
65 patients who did not completed 
symptom diaries 
p-value 
Age (years), median (IQR) 59.36 (46.74 – 68.22) 45.02 (36.33 – 53.79) <0.001 
Female patients, n (%) 41 (59) 36 (55) 0.73 
IgG trough level (g/l)*, median (IQR) 9.0 (8.0 – 10.0) 9.0 (7.8 – 10.6) 0.99 
Prophylactic antibiotic, n (%) 45 (65)   
   Amoxicillin, n (%) 7 (10)   
   Azithromycin, n(%) 22 (32)   
   Ciprofloxacin, n (%) 3 (4)   
   Clarithromycin, n (%) 3 (4)   
   Co-amoxiclav, n(%) 2 (3)   
   Cotrimoxazole, n (%) 2 (3)   
   Doxycycline, n (%) 4 (6)   
   Lymecycline, n (%) 1 (1)   
   Penicillin, n (%) 1 (1)   
Current smoker, n (%) 6 (9) 4 (6) 0.92 
Past smoker, n (%) 15 (22) 15 (23) 
Never smoker, n (%) 48 (70) 46 (71) 
Bronchiectasis on CT, n (%) 37 (57.81) 29 (49.15) 0.22 
BSI score†, median (IQR) 3.5 (2 - 6) 2 (1-4) 0.01 
FEV1 (l)‡, median (IQR) 2.24 (1.80 – 3.23) 2.63 (2.12 - 3.36) 0.11 
FEV1 predicted (%)§, median (IQR) 93.2 (73.3 - 102.9) 93.5 (74.6 - 105.4) 0.95 
SGRQ** Total scores, median (IQR) 24.47 (8.41 - 45.54)   
   SGRQ Symptoms score, 
   median (IQR) 
39.28 (23.76 - 58.56)   
   SGRQ Activity score, 
   median (IQR) 
29.31 (5.96 - 59.46)   
   SGRQ Impact score, 
   median (IQR) 
14.90 (1.98- 29.90)   
 
*IgG trough level, serum immunoglobulin G level measured immediately before the following immunoglobulin replacement 
is administered.  †Bronchiectasis severity Index (BSI), ranging from 0 (best) to 25 (worst), a validated multi-component score 
in bronchiectasis which predicts future risk of exacerbations, hospitalisations and mortality.  ‡FEV1, forced expiratory 
volume in one second.  §FEV1 predicted, proportion of actual FEV1 versus predicted forced expiratory volume in one second 
in accordance with ERS guidelines of 1993.  **St George’s Respiratory Questionnaire (SGRQ), a validated measure of 
respiratory health-status scored between 0 (best) and 100 (worst) quality of life.  P-values were calculated using to a 
Wilcoxon Ranksum test for continuous variables and Fisher's exact test for categorical variables. 
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Legends 
Figure 1. Study design and analysis flow chart.  Out of 134 CVID patients, 69 completed a 
symptom diary for investigation 1 and 41 provided microbiological samples for investigation 
2. Details of further analyses and the numbers of participants included for each are provided. 
CVID, Common Variable Immunodeficiency; SGRQ, St George’s Respiratory Questionnaire.  
 
Figure 2. Characterisation of respiratory exacerbations treated with antibiotics. 
Symptom prevalence (%) and total symptom count (TSC) are displayed over time (days) for 
76 antibiotic-treated respiratory exacerbations in CVID patients.  Bar diagram reflects mean 
(SD) total symptom count.  Day 1 is defined as start of oral antibiotic therapy (OAT).  URTS, 
upper respiratory tract symptoms. 
 
Figure 3. Trigger Symptom Analysis for CVID patients to commence antibiotic therapy. 
A. Prospective diary data of respiratory symptoms and oral antibiotic therapy (OAT) usage 
was collected from 69 CVID patients. The forest plot displays odds ratios and 95%-CI as a 
measure of effect size for individual symptoms to trigger the start of OAT (higher odds ratios 
imply a strong association between the symptom and starting OAT).  Results are derived from 
univariate and multivariate logistic regression based on 5446 observations (days).  URTS, 
upper respiratory tract symptoms; SoB, shortness of breath; ISV, increased sputum volume. 
B. Bar graph shows the proportion of patients initiating OAT on each of the first 14 days of 
consecutive symptoms.  The time since start of symptoms is defined as the number of days for 
which two or more symptoms were present.  The OAT initiation proportion is the proportion 
of OAT which was started after a specific time since start of symptoms.   
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Figure 4. Antibiotic Response Analysis of predictor symptoms. Kaplan-Meier plots display 
time until recovery based on 76 antibiotic-treated respiratory exacerbations in CVID patients: 
(A) for all exacerbations, (B) according to presence or absence of upper respiratory tract 
symptoms (URTS), (C) according to presence or absence of sore throat (ST), and (D) 
according to presence or absence of purulent sputum (PS) . 
E. Forest plot displays hazard ratios for time until recovery after start of oral antibiotic 
therapy (OAT) depending on the presence of specific symptoms.  A multivariate Cox model 
was calculated for all symptoms which proved to be significant in univariate analysis 
(multivariate data are only shown for these variables).  Hazard ratio reflects the ‘risk’ for 
earlier complete symptomatic remission over time.  
SoB, shortness of breath, ISV, increased sputum volume; CI, confidence interval. 
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Figure 5. Pathogenic Viruses and Bacteria Analysis.  Viral and bacterial pathogens are 
frequently isolated in CVID-related respiratory exacerbations.  A. Viral PCR was 
performed on nasopharyngeal swabs in 54 symptomatic respiratory exacerbations in CVID 
patients. No pathogen (grey) was found in 24 (44%) exacerbations.  A pathogenic virus was 
found in 30 (56%) exacerbations.  Rhinovirus was found in 18 (33%) exacerbations; among 
those where two co-infections with Adenovirus (Adeno), two with Respiratory Syncytial 
Virus (RSV), and one with Human metapneumovirus (hMPV). 
B. Bacterial culture was performed on spontaneously expectorated sputum in 43 symptomatic 
respiratory exacerbations in CVID patients. No pathogen (grey) was found in 29 (67%) 
exacerbations.  A pathogenic bacterium was found in 14 (33%) exacerbations.  Pseudomonas 
aeruginosa was isolated in three (7%) exacerbations; among those was one co-infection with 
Streptococcus pneumoniae.  Two patients (accounting for four exacerbations) were probably 
